Hyperuricemia and chronic heart failure: risk factors and prognostic parallels

Cover Page

Cite item

Full Text

Abstract

Background. Hyperuricemia has been considered as the risk factors for cardiovascular diseases in recent years. However, an ambiguous position remains regarding the association of hyperuricemia with a number of cardiometabolic conditions and chronic heart failure (CHF). Aim. To present data on the causes of hyperuricemia, its association with heart failure and the impact on the prognosis of patients with this syndrome. Materials and methods. The search for publications in search systems over the past 15 years was done. The review includes articles from peer-reviewed literature. Results. Many researchers have shown that hyperuricemia is associated with cardiovascular diseases, but studies with Mendelian randomization have not shown conclusive evidence of this association. Changes in the human body from the initiation of risk factors to the clinical symptoms can be both the cause of hyperuricemia and its consequence. Existing data indicate the development of hemodynamic and metabolic changes on the background of activation of neurohumoral systems, which may underlie the close association of hyperuricemia and heart failure, including the worse prognosis. Conclusion. Hyperuricemia is a component of complex pathophysiological, hemodynamic and inflammatory processes, which is why uric acid control in all patients with heart failure is important in order to detect decompensation or disease progression in a timely manner. Key words: risk factor, uric acid, hyperuricemia, heart failure, prognosis. For citation: Larina V.N., Larin V.G. Hyperuricemia and chronic heart failure: risk factors and prognostic parallels. Consilium Medicum. 2020; 22 (5): 62-66. DOI: 10.26442/20751753.2020.5.200158

About the authors

Vera N. Larina

Pirogov Russian National Research Medical University

д-р мед. наук, зав. каф. поликлинической терапии лечебного фак-та Moscow, Russia

Vladimir G. Larin

Pirogov Russian National Research Medical University

Email: larinav@mail.ru
канд. мед. наук, доц. каф. поликлинической терапии лечебного фак-та Moscow, Russia

References

  1. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гипер-урикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8-21. doi: 10.26442/2075082X.2019.4.190686
  2. Артериальная гипертензия у взрослых. Клинические рекомендации. Российское кардиологическое общество. Год утверждения 2020. http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf
  3. Ventura HO, Stewart MH, Lavie CJ. New guidelines, increasing hypertension numbers, resistance and resistance to change. Mayo Clin Proc 2019; 94: 745-7.
  4. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН - РКО -РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (6S): 8-158. doi: 10.18087/cardio.2475
  5. Li Q, Li X, Wang J et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019; 9: e026677. DOI: 10.1136/ bmjopen-2018-026677
  6. Bardin T, Richette P Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014;(2): 186-91. doi: 10.1097/BOR.0000000000000028
  7. Chales G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine 2019; 86 (4): 437-43.
  8. Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology 2017; 56 (5): 679-88. doi: 10.1093/rheumatology/kew293
  9. Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-71.
  10. See L, Kuo C, Chuang F et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009; 36 (8): 1691-8.
  11. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021-104. doi: 10.1093/eurheartj/ehy339
  12. Kei A, Koutsouka F, Makri A et al. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract 2018; 72: e13048.
  13. Keenan T, Zhao W, Rasheed A et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016; 67: 407-16.
  14. Cho S, Chang Y, Kim I, Ryu S. U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol 2018; 70: 1122-32.
  15. White J, Sofat R, Hemani G et al. UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a Mendelian radomisation analysis. Lancet Diabetes Endocrinol 2016; 4 (4): 32736. doi: 10.1016/S22138587(15)00386-1
  16. Kaufman M, Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev 2013; 18 (2): 177-86. doi: 10.1007/s10741-012-9322-2
  17. Doehner W, Springer J, Anker S. Uric acid in chronic heart failure - current pathophysiological con-septs. Letter to the Editor. Eur J Heart Fail 2008; 10: 1269-70.
  18. Zhang S, Cheng J, Huandfu N et al. Hyperuricemia and Cardiovascular Disease. Clin Pharm Des 2019; 25 (6): 700-9. doi: 10.2174/1381612825666190408122557
  19. Sun M, Vazquez A, Reynolds R et al. Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther 2018, 20: 90.
  20. Ochiai M, Baretto A, Oliveira M et al. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005; 7: 468-74.
  21. Ларина В.Н., Барт Б.Я., Ларин В.Г., Донсков А.С. Высокая концентрация сывороточной мочевой кислоты: клиническое и прогностическое значение при хронической сердечной недостаточности. Кардиология. 2016; 5: 68-75.
  22. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556-62.
  23. Holme I, Aastveit A, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk Study (AMORIS). J Intern Med 2009; 266 (6): 558-70.
  24. Krishnan E, Hariri A, Dabbous O et al. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 2012; 18 (3): 138-43.
  25. Huang H, Huang B, Li Y et al. Uric Acid and risk of heart failure: a systematic review and meta-ana-lysis. Eur J Heart Fail 2014; 16 (1): 15-24.
  26. Cavarretta E, Frati G, Sciarretta S. Visit-to-Visit Systolic Blood Pressure Variability and Cardiovascular Outcomes: New Data From a Real-World Korean Population. Am J Hypertens 2017; 30: 5503. doi: 10.1093/ajh/hpx055
  27. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376: 1332-40. doi: 10.1056/NEJMoa1606148
  28. Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS One 2019; 14 (8): e0220532. doi: 10.1371/journal.pone.0220532
  29. Filippatos G, Ahmed M, Gladden J et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011; 32:712-20.
  30. Ogino K, Kato M, Furuse Y, Kinugasa Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010; 3 (1): 73-81.
  31. Ларина В.Н., Барт Б.Я., Вартанян Е.А. Факторы, влияющие на декомпенсацию хронической сердечной недостаточности у лиц пожилого возраста. Рациональная фармакотерапия в кардиологии. 2013; 9 (1): 15-24.
  32. Manzano L, Babalis D, Roughton M et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528-36.
  33. Alcaino H, Greig D, Chiong M et al. Serum acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646-51.
  34. Anker S, Doehner N, Raucchaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation 2003; 107: 1991-7.
  35. Ларина В.Н., Барт Б.Я., Бродский М.С. Клиническое и прогностическое значение гиперурикемии при хронической сердечной недостаточности у больных пожилого возраста. Журнал Сердечная Недостаточность. 2011; 5 (67): 277-81.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies